Compound News and Research

RSS

Global home health management market expanding at CAGR of 10% through 2012

Remote health management is the fastest growing segment of a burgeoning home health management market. However, RHM’s full potential will materialize only if health insurers adopt reimbursement practices that encourage greater physician adoption, concludes Scientia Advisors, a global strategy consulting firm, in its review of the worldwide home health management market released today.

26 Mar 2010

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco, Ph.D., Vice President of Pharmaceutical Development, will be presenting at the 3rd International Scar Club Meeting in Montpellier, France on March 26, 2010.

26 Mar 2010

NYU researchers identify novel therapy for rheumatoid arthritis

By enhancing the activity of immune cells that protect against runaway inflammation, researchers at NYU Langone Medical Center may have found a novel therapy for rheumatoid arthritis and other autoimmune diseases.

26 Mar 2010

FIMM to launch cell microarray screening research program utilizing Aushon 2470 Arrayer technology

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis announced today that the Institute for Molecular Medicine Finland will launch a cell microarray screening research program utilizing the Aushon 2470 Arrayer technology.

26 Mar 2010

Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial

Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will continue enrolling to the preset goal of 2,000 patients. As part of a planned interim analysis, an independent Data Monitoring Committee (DMC) has evaluated efficacy and safety data on the first 1,500 subjects to complete the 28-day follow-up in the Phase III ACCESS trial.

26 Mar 2010

DARA BioSciences announces the initiation of Phase I clinical study for DB959

DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.

26 Mar 2010

Natural chemicals from blackcurrants may reduce lung inflammation in allergy-induced asthma

A preliminary study by New Zealand company Plant & Food Research shows that natural chemicals from blackcurrants may help breathing in some types of asthma.

26 Mar 2010

Beaumont Hospital opens women's urology center

It’s something that women don’t talk about even to their best friends or their doctors. That’s why Beaumont Hospitals has created a new Women’s Urology Center offering leading-edge treatments, innovative research and the most advanced minimally invasive procedures for women’s urological conditions such as incontinence, pelvic pain and sexual dysfunction.

25 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

Study: MetAP inhibitors prevent TB growth in test tubes

Suspecting that a particular protein in tuberculosis was likely to be vital to the bacteria's survival, Johns Hopkins scientists screened 175,000 small chemical compounds and identified a potent class of compounds that selectively slows down this protein's activity and, in a test tube, blocks TB growth, demonstrating that the protein is indeed a vulnerable target.

25 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

Washington State mercury-limit suspension for swine flu vaccine ends

When it comes to some diseases prevention still is better than cure and swine flu is one such disease. The sheer global panic that gripped nations last year is hard to forget. The PanvaxH1N1 vaccine is specifically manufactured to target the influenza (A) H1N1 strain known more popularly as swine flu. Getting the flu shots may be crucial in prevention of spread of the highly contagious disease. Health officials say that the H1N1 strain of flu is still circulating but at low levels.

24 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

Researchers develop new compound to inhibit HIV transmission

A compound that can inhibit the transfer of HIV from one cell to another has been developed by researchers at the Institut de Biologie Structurale Jean-Pierre Ebel.

22 Mar 2010

Executive order on abortion funding to assuage anti-choice members: Center for Reproductive Rights concerned

News reports today confirm that an executive order on abortion funding is being developed in an attempt to assuage anti-choice members of the House of Representatives and to secure their votes in the down-to-the-wire battle over passage of healthcare reform. The text of the proposed executive order has not been publicly disclosed. Nancy Northup, president of the Center for Reproductive Rights has this response:

22 Mar 2010

Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate

Today, Formatech, Inc. announces the selection of Tracon Pharmaceuticals’ TRC102 clinical product as the next Fillanthropy™ Program candidate. Under this program, Formatech donates the services required to aseptically fill and finish one lot of the drug candidate to support Tracon’s upcoming clinical trials.

22 Mar 2010

Valeant Pharmaceuticals International advances dermatology presence in Brazilian market

Valeant Pharmaceuticals International today announced that it has signed a binding agreement to acquire a private branded generics and over the counter company located in Brazil for approximately US$28 million. A large portion of the company's product portfolio is in dermatology and the company had annual sales of approximately US$19 million in 2009.

19 Mar 2010

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

A collaborative project between Sanford-Burnham Medical Research Institute at Lake Nona and Analiza, Inc. has yielded aqueous solubility data for over 20,000 compounds in the NIH Molecular Library within the first 90 days of screening and characterization.

19 Mar 2010

New report on the state of U.S. mobile health market

CSMG, the strategy division of TMNG Global, a leading provider of professional services, products and services to the converging communications, media and entertainment industries, today released its report on the state of the U.S. mobile health market, entitled: mHealth: Taking the Pulse.

19 Mar 2010

Compound News and Research

Global home health management market expanding at CAGR of 10% through 2012

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

NYU researchers identify novel therapy for rheumatoid arthritis

FIMM to launch cell microarray screening research program utilizing Aushon 2470 Arrayer technology

Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial

DARA BioSciences announces the initiation of Phase I clinical study for DB959

Natural chemicals from blackcurrants may reduce lung inflammation in allergy-induced asthma

Beaumont Hospital opens women's urology center

Evotec AG reports financial results and corporate updates for 2009

Study: MetAP inhibitors prevent TB growth in test tubes

Æterna Zentaris announces 2009 financial and operating results

Washington State mercury-limit suspension for swine flu vaccine ends

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

ChemoCentryx undertakes Phase II clinical trial of CCX140

Researchers develop new compound to inhibit HIV transmission

Executive order on abortion funding to assuage anti-choice members: Center for Reproductive Rights concerned

Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate

Valeant Pharmaceuticals International advances dermatology presence in Brazilian market

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

New report on the state of U.S. mobile health market

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News